Tekla Life Sciences Investors HQL
We take great care to ensure that the data presented and summarized in this overview for TEKLA LIFE SCIENCES INVESTORS is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HQL
View all-
Saba Capital Management, L.P. New York, NY1.42MShares$19.3 Million0.39% of portfolio
-
Cornerstone Advisors, LLC Asheville, NC494KShares$6.72 Million0.29% of portfolio
-
1607 Capital Partners, LLC Richmond, VA480KShares$6.53 Million0.45% of portfolio
-
Allspring Global Investments Holdings, LLC431KShares$5.86 Million0.01% of portfolio
-
Morgan Stanley New York, NY430KShares$5.85 Million0.0% of portfolio
-
Aqr Arbitrage LLC Greenwich, CT384KShares$5.22 Million0.38% of portfolio
-
Clough Capital Partners L P Boston, MA375KShares$5.1 Million0.57% of portfolio
-
Rpo LLC Stamford, CT339KShares$4.6 Million7.22% of portfolio
-
Needham Investment Management LLC New York, NY314KShares$4.26 Million0.55% of portfolio
-
Flagship Harbor Advisors, LLC284KShares$3.86 Million0.25% of portfolio
Latest Institutional Activity in HQL
Top Purchases
Top Sells
About HQL
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Insider Transactions at HQL
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 02
2024
|
Saba Capital Management, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
26,274
+0.85%
|
$341,562
$13.46 P/Share
|
May 01
2024
|
Saba Capital Management, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
252
+0.01%
|
$3,276
$13.02 P/Share
|
Apr 30
2024
|
Saba Capital Management, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
16,573
+0.54%
|
$215,449
$13.13 P/Share
|
Apr 26
2024
|
Saba Capital Management, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
120,304
+3.82%
|
$1,563,952
$13.0 P/Share
|
Apr 25
2024
|
Saba Capital Management, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
97,574
+3.25%
|
$1,170,888
$12.99 P/Share
|
Apr 24
2024
|
Saba Capital Management, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
20,529
+0.73%
|
$266,877
$13.12 P/Share
|
Apr 23
2024
|
Saba Capital Management, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
48,203
+1.7%
|
$626,639
$13.15 P/Share
|
Apr 22
2024
|
Saba Capital Management, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,022
+0.07%
|
$24,264
$12.88 P/Share
|
Apr 19
2024
|
Saba Capital Management, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
42,459
+1.53%
|
$509,508
$12.84 P/Share
|
Apr 18
2024
|
Saba Capital Management, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
81,738
+2.94%
|
$980,856
$12.8 P/Share
|
Apr 09
2024
|
Kathleen Goetz Director |
BUY
Open market or private purchase
|
Direct |
400
+26.94%
|
$5,200
$13.32 P/Share
|
Jan 02
2024
|
Todd Reit Director |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$13,000
$13.8 P/Share
|
Dec 28
2023
|
Bill Maher Director |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$13,000
$13.57 P/Share
|
Sep 25
2023
|
Daniel R Omstead President |
BUY
Open market or private purchase
|
Direct |
10,096
+4.86%
|
$121,152
$12.39 P/Share
|
Sep 20
2023
|
Daniel R Omstead President |
BUY
Open market or private purchase
|
Direct |
12,000
+6.02%
|
$144,000
$12.68 P/Share
|
Mar 23
2022
|
Kathleen Goetz Director |
BUY
Open market or private purchase
|
Direct |
92
+11.84%
|
$1,472
$16.27 P/Share
|
Jan 26
2022
|
Kathleen Goetz Director |
BUY
Open market or private purchase
|
Direct |
593
+50.0%
|
$10,081
$17.54 P/Share
|
Aug 11
2021
|
Daniel R Omstead President |
BUY
Open market or private purchase
|
Direct |
6,403
+4.19%
|
$134,463
$21.63 P/Share
|
Oct 26
2020
|
Daniel R Omstead President |
BUY
Open market or private purchase
|
Direct |
6,175
+4.47%
|
$104,975
$17.52 P/Share
|
Oct 21
2020
|
Daniel R Omstead President |
BUY
Open market or private purchase
|
Direct |
5,950
+4.52%
|
$101,150
$17.75 P/Share
|
Last 12 Months Summary
Open market or private purchase | 480K shares |
---|